

Viscosupplementation Market by Type (Single Injection, Three Injection, Five Injection), Age Group (Adults, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Others), End Use (Hospitals, Orthopedic Clinics, and Others), and Region 2024-2032

Market Report | 2024-01-30 | 149 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3899.00
- Five User Licence \$4899.00
- Enterprisewide License \$5899.00

Report description:

The global viscosupplementation market size reached US\$ 4.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 7.42% during 2024-2032. The increasing prevalence of osteoporosis and osteoarthritis (OA) and the shifting consumer inclination toward minimally invasive non-surgical treatments represent some of the key factors driving the market.

Viscosupplementation represents a minimally invasive medical procedure wherein intraarticular injection comprising gel-like fluid known as exogenous hydraulic acid (HA) derivatives are directly administered into the knee joints of the patient. It acts as a lubricant, which enables bones to move smoothly over each other, lowers inflammation, and performs as a shock absorber for joint loads. Viscosupplementation reduces the friction during the movements, assists the synovial fluids in creating more cushion, eliminates severe pain, and enhances the range of movements or motions of the joint. Apart from this, it restores the rheological properties of the synovial fluids, which produce mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation is extensively utilized in the treatment of knee, hip, and hand osteoarthritis. Currently, it is mainly available in intermediate, low, and high molecular weights.

Viscosupplementation Market Trends:

The increasing prevalence of osteoporosis and osteoarthritis (OA) represents one of the key factors driving the market growth. In

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

line with this, the shifting consumer inclination toward the minimally invasive non-surgical treatment options has facilitated the widespread adoption of viscosupplementation in the healthcare sector for corticosteroids and joint pain management. This, in turn, is acting as another major growth-inducing factor. This is further influenced by the growing consumer awareness regarding the multiple benefits of non-surgical treatments, including no hospitalization, fewer expenses, minimal complications, and better clinical outcomes and recovery rates. Additionally, the favorable government initiatives and significant investments by various pharmaceutical companies to launch novel drugs and different routes of administrations is supporting the market growth.

Moreover, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscle, spine, and nerves, is favoring the market growth. Furthermore, the introduction of open-label single-injections with hydraulic acid is propelling the market growth. Apart from this, favorable health insurance reimbursement policies, the rising geriatric population, which is susceptible to chronic ailments, increasing number of individuals with chronic disability, collaborations and partnership among the key players, and continuous research and development (R&D) activities in the field of medical sciences are positively impacting the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global viscosupplementation market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, age group, distribution channel, application and end use.

Single Injection
Three Injection
Five Injection

Type Insights:

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the type. This includes single, three and five injection. According to the report, single injection represented the largest segment.

Age Group Insights:

Adults

Geriatrics

A detailed breakup and analysis of the viscosupplementation market based on the age group has also been provided in the report. This includes adults and geriatric. According to the report, geriatrics accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacies Retail Pharmacies Online Pharmacies

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Application Insights:

Scotts International, EU Vat number: PL 6772247784

Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others

A detailed breakup and analysis of the viscosupplementation market based on the application has also been provided in the report. This includes knee, hip and hand osteoarthritis. According to the report, knee osteoarthritis accounted for the largest market share.

End Use Insights:

Hospitals

Orthopedic Clinics

Others

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the end use. This includes hospitals, orthopedic clinics, and others. According to the report, orthopedic clinics represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the

Scotts International. EU Vat number: PL 6772247784

United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, the North America was the largest market for viscosupplementation. Some of the factors driving the North America viscosupplementation market included the rising geriatric population and the affordable health insurance reimbursement policies.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global viscosupplementation market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited), etc.

Key Questions Answered in This Report:

How has the global viscosupplementation market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global viscosupplementation market?

What are the key regional markets?

Which countries represent the most attractive viscosupplementation markets?

What is the breakup of the market based on the type?

What is the breakup of the market based on the age group?

What is the breakup of the market based on the distribution channel?

What is the breakup of the market based on the application?

What is the breakup of the market based on the end use?

What is the competitive structure of the global viscosupplementation market?

Who are the key players/companies in the global viscosupplementation market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Viscosupplementation Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1 Single Injection
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Three Injection
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Five Injection
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 7 Market Breakup by Age Group
- 7.1 Adults
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Geriatrics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 9 Market Breakup by Application
- 9.1 Knee Osteoarthritis
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Hip Osteoarthritis
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Hand Osteoarthritis
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 10 Market Breakup by End Use
- 10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Orthopedic Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Others

Scotts International. EU Vat number: PL 6772247784

- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
 - 11.1.1.1 Market Trends
 - 11.1.1.2 Market Forecast
- 11.1.2 Canada
 - 11.1.2.1 Market Trends
 - 11.1.2.2 Market Forecast
- 11.2 Asia-Pacific
- 11.2.1 China
 - 11.2.1.1 Market Trends
 - 11.2.1.2 Market Forecast
- 11.2.2 Japan
 - 11.2.2.1 Market Trends
 - 11.2.2.2 Market Forecast
- 11.2.3 India
 - 11.2.3.1 Market Trends
 - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
 - 11.2.4.1 Market Trends
 - 11.2.4.2 Market Forecast
- 11.2.5 Australia
 - 11.2.5.1 Market Trends
 - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
 - 11.2.6.1 Market Trends
 - 11.2.6.2 Market Forecast
- 11.2.7 Others
 - 11.2.7.1 Market Trends
 - 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
 - 11.3.1.1 Market Trends
 - 11.3.1.2 Market Forecast
- 11.3.2 France
 - 11.3.2.1 Market Trends
 - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
 - 11.3.3.1 Market Trends
 - 11.3.3.2 Market Forecast
- 11.3.4 Italy
 - 11.3.4.1 Market Trends
 - 11.3.4.2 Market Forecast
- 11.3.5 Spain
 - 11.3.5.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

- 11.3.5.2 Market Forecast
- 11.3.6 Russia
 - 11.3.6.1 Market Trends
 - 11.3.6.2 Market Forecast
- 11.3.7 Others
 - 11.3.7.1 Market Trends
 - 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
 - 11.4.1.1 Market Trends
 - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
 - 11.4.2.1 Market Trends
 - 11.4.2.2 Market Forecast
- 11.4.3 Others
 - 11.4.3.1 Market Trends
 - 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
- 12 Drivers, Restraints, and Opportunities
- 12.1 Overview
- 12.2 Drivers
- 12.3 Restraints
- 12.4 Opportunities
- 13 Value Chain Analysis
- 14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
- 15 Price Analysis
- 16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Anika Therapeutics Inc.
 - 16.3.1.1 Company Overview
 - 16.3.1.2 Product Portfolio
 - 16.3.1.3 Financials
 - 16.3.1.4 SWOT Analysis
- 16.3.2 Aptissen S.A.
 - 16.3.2.1 Company Overview
 - 16.3.2.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

- 16.3.3 Bioventus LLC
 - 16.3.3.1 Company Overview
 - 16.3.3.2 Product Portfolio
 - 16.3.3.3 Financials
- 16.3.4 Ferring Pharmaceuticals
 - 16.3.4.1 Company Overview
 - 16.3.4.2 Product Portfolio
- 16.3.5 Fidia Farmaceutici S.p.A.
 - 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.6 Johnson & Johnson
 - 16.3.6.1 Company Overview
 - 16.3.6.2 Product Portfolio
 - 16.3.6.3 Financials
 - 16.3.6.4 SWOT Analysis
- 16.3.7 LG Chem Ltd.
 - 16.3.7.1 Company Overview
 - 16.3.7.2 Product Portfolio
 - 16.3.7.3 Financials
 - 16.3.7.4 SWOT Analysis
- 16.3.8 OrthogenRx Inc. (Avanos Medical Inc.)
 - 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.9 Sanofi S.A.
 - 16.3.9.1 Company Overview
 - 16.3.9.2 Product Portfolio
 - 16.3.9.3 Financials
 - 16.3.9.4 SWOT Analysis
- 16.3.10 Seikagaku Corporation
 - 16.3.10.1 Company Overview
 - 16.3.10.2 Product Portfolio
 - 16.3.10.3 Financials
- 16.3.11 Virchow Biotech Private Limited
 - 16.3.11.1 Company Overview
 - 16.3.11.2 Product Portfolio
- 16.3.12 Zimmer Biomet
 - 16.3.12.1 Company Overview
 - 16.3.12.2 Product Portfolio
 - 16.3.12.3 Financials
 - 16.3.12.4 SWOT Analysis
- 16.3.13 Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited)
 - 16.3.13.1 Company Overview
 - 16.3.13.2 Product Portfolio



To place an Order with Scotts International:

Print this form

Viscosupplementation Market by Type (Single Injection, Three Injection, Five Injection), Age Group (Adults, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Others), End Use (Hospitals, Orthopedic Clinics, and Others), and Region 2024-2032

Market Report | 2024-01-30 | 149 pages | IMARC Group

Complete the	elevant blank fields and sign			
☐ - Send as a sca	nned email to support@scotts-internation	onal.com		
ORDER FORM:				
Select license	License			Price
	Electronic (PDF) Single User			\$3899.00
Five User Licence				\$4899.00
Enterprisewide License			\$5899.00	
				VAT
			-	Total
	vant license option. For any questions pleas at 23% for Polish based companies, individu			
Lillali		THORE		
First Name*		Last Name*		
ob title*				
Company Name*		EU Vat / Tax ID / NI	P number*	

Scotts International. EU Vat number: PL 6772247784

Address*	City*	
Zip Code*	Country*	
	Date	2025-05-07
	Signature	